Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Data available 2H from Phase III study of Empliciti in first-line multiple myeloma

Source Link:: http://d1lge852tjjqow.cloudfront.net/CIK-0000014272/e9b46f5e-5aac-4235-a465-d6d35bb1aa20.pdf?noexit=true

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

BMY

100%

ABBV

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Empliciti is a humanized monoclonal antibody currently approved for treatment of multiple myeloma in combination with Revlimid. Developed by AbbVie and Bristol0Myers Squibb, Empliciti is currently in several Phase 3 trials, with one testing the efficacy and safety due to release results in 2016.

http://d1lge852tjjqo...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jun 24, 2017

Occurred Source:

https://news.bms.com/press-release/corporatefinancial-news/four-year-follow-empliciti-elotuzumab-plus-lenalidomidedexamet

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Multiple Myeloma, Empliciti, Elotuzumab